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Abstract
In a respiratory-infection-model with the avian influenza A H9N2 virus we studied lung and splenic immune reactions in chickens using a
recently developed 5K chicken immuno-microarray. Groups of chickens were either mock-immunized (referred to as non-immune), vaccinated
with inactivated viral antigen only (immune) or with viral antigen in a water-in-oil (W/O) immunopotentiator (immune potentiated). Three
weeks after vaccination all animals were given a respiratory infection. Immune potentiated birds developed inhibitory antiviral antibodies,
showed minimal lung histopathology and no detectable viral sequences, while non-immune animals showed microscopic immunopathology
and detectable virus. Immune birds, receiving antigen in saline only, showed minimal microscopic histopathology, and intermediate levels
of virus detection. These classical features in the different groups were mirrored by overlapping or specific mRNA gene expression profiles
in lungs and spleen using microarray analysis. To our knowledge this is the first study demonstrating pneumonia-associated lung pathology
of the low pathogenic avian influenza H9N2 virus. Our data provide insights into the molecular interaction of this virus with its natural host
when naive or primed by vaccination.
© 2006 Elsevier Ltd. All rights reserved.
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1. Introduction
Avian influenza (AI) infections are carefully monitored
because of their negative effects on intensive poultry rearing
systems, but also in view of occasional diseases in humans
and fear for pandemic spreading. Our understanding of in vivo
influenza pathogenesis and host immunity is limited, despite
considerable experimental knowledge generated mainly in
mouse and ferret models. As chickens are natural hosts
for respiratory influenza infections, understanding influenza
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∗∗ Corresponding author. Tel.: +31 485 587688; fax: +31 485 585313.
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immunity in its host is not only an important issue in the poul-
try industry, but may also provide key insights into immune
pathways required for prophylactic or therapeutic protection
of other influenza hosts, and possibly even against other res-
piratory viruses.
Antiviral protection generally requires an orchestration of
innate, and if necessary, adaptive immune cells. The tools to
study immunological responses in chicken are limited when
compared to those available in the mouse and human sys-
tem. Recently, we and others have identified and cloned the
genes that encode novel immunoregulatory response mod-
ifiers of the chicken [1–4] which, in general, show limited
sequence homology to known mammalian genes. In addi-
tion, numerous chicken gene sequences are now available
through the recently assembled chicken genome [5]. These
0264-410X/$ – see front matter © 2006 Elsevier Ltd. All rights reserved.
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sequence data allow analysis at the transcriptional level of
potential immunorelevant molecules, although the effect of
posttranslational gene expression cannot be measured and
secure functional annotation requires confirmation in future
investigations.
For the chicken study described in this paper we used the
avian influenza A subtype H9N2 (isolate A/Chicken/United
Arab Emirates/99). This serotype is pathotyped as low
pathogenic, according to the OIE classification and certified
by CVL Weybridge, but is able to produce a severe infec-
tion in the context of opportunistic secondary pathogens,
such as infectious bronchitis virus (IBV) or Mycoplasma gal-
lisepticum [6]. On the other hand, it was shown that H9N2
viruses evoked cross-protective CTL-based cellular immu-
nity in chickens against a highly pathogenic H5N1 infection
[7,8]. Influenza A virus is a member of the Orthomyxoviridae
family of segmented, negative-stranded RNA viruses. Avian
influenza A subtype H9N2 viruses can transmit to mam-
malian species, including humans [9,10]. Its transmission to
humans, combined with genetic reassortment or mutation,
raised anxiety for a potential pandemic spread in the human
population [11,12].
Apart from classical assays, such as histopathology and
antiviral antibody titers, we analyzed gene expression pro-
files, using a newly designed chicken immune-microarray
[13]. With this cDNA microarray we studied host gene
expression in the lungs and spleen of non-immune (mock-
immunized), immune (immunized with inactivated H9N2
antigen in saline), and immune potentiated (immunized with
inactivated H9N2 in a water-in-oil emulsion) chickens under-
going a primary respiratory infection with live H9N2. We
questioned whether lung pathology and immunity-associated
gene pathways could be identified in non-immune birds and
whether they (partially) overlap with those in primed birds.
We also aimed to identify primed memory immune path-
ways in immune and immune potentiated animals and ques-
tioned whether they differ from natural immune pathways in
infected non-immune birds. In addition we tested whether
viral replication was affected by immunization.
From our study we conclude that immune potentiated birds
developed inhibitory antiviral antibodies, showed minimal
lung histopathology and no detectable viral sequences, while
non-immune animals showed microscopic immunopathol-
ogy and detectable virus. Immune birds, receiving antigen in
saline only, showed minimal overall microscopic histopathol-
ogy, and intermediate levels of virus detection. These classi-
cal features were compared with host mRNA gene expression
profiles in lungs and spleen using microarray analysis.
2. Materials and methods
2.1. Animals
Three-week-old chickens (S5 inbred broiler type) were
derived from Hybro/Euribrid (Boxmeer, the Netherlands) and
housed under SPF conditions. The animals received food and
water ad libitum. In compliance with the Dutch law, all exper-
iments were carried out according to protocols approved by
the Intervet Animal Welfare Committee.
2.2. H9N2 virus and antigen preparation
Avian influenza A subtype H9N2 virus (isolate
A/Chicken/United Arab Emirates/99) was produced in eggs
using routine procedures. For the experimental vaccine for-
mulation the aqueous phase containing the virus suspension,
diluted in 0.01 M phosphate buffer (pH 7.2), was formalin-
inactivated. This formalin-inactivated antigen preparation
was formulated into saline or into an immunopotentiating
mineral oil-based W/O emulsion according to standard pro-
cedures using a high speed mixing device (ultra-thurrax) [14].
2.3. Experimental immunization protocol
Distinct groups (n = 3) of 3-week-old chickens were i.m.
vaccinated in the leg muscle (see also Table 1) with either
0.25 ml saline (naive and non-immune control groups), with
0.25 ml formalin inactivated avian influenza H9N2 antigen
in saline (immune group), or with inactivated avian influenza
H9N2 antigen formulated in an immunopotentiating min-
eral oil-based W/O emulsion (45/55, v/v) (immune poten-
tiated group). Blood samples were taken at 0 and 3 weeks
post-vaccination. At 3 weeks post-vaccination all groups,
except the naive control group, were infected (challenged)
via the oculo-nasal plus intratracheal route with a total dose
of 10e8.8 ED50 H9N2 virus (i.e. 0.1 ml/eye, 0.1 ml/nostril,
0.2 ml into the trachea). At 1 and 5 days post-infection chick-
ens were sacrificed and the lungs and spleens were isolated
for histopathology and RNA isolation (see also Fig. 1 for a
time scheme).
2.4. HI-assay for antiviral H9-antibodies
Serum levels of H9-specific antibodies were determined
by a haemagglutination inhibition (HI) assay. Serial two-fold
serum dilutions were prepared in microtiter plates and mixed
with an equal volume containing eight haemagglutinating
units/50l H9N2 antigen. Titers are expressed as the recip-
rocal of the highest dilution that gives complete inhibition
of haemagglutination of chicken red blood cells (1%, v/v in
buffered saline). Samples were regarded positive for inhibi-
tion of haemagglutination at a dilution ≥1:2.
Table 1
Set up of the experimental vaccination and challenge
Group Antigen Adjuvant Challenge Sacrifice date
Naive control – Saline No 1 d
Non-immune control – Saline Yes 1 d and 5 d p.i.
Immune H9N2 Saline Yes 1 d and 5 d p.i.
Immune potentiated H9N2 W/O Yes 1 d and 5 d p.i.
d = day(s); p.i. = post-infection (challenge).
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Fig. 1. Time line of the chicken study. After challenge infection, one half of the birds had a 1-day endpoint (day 43), the other half a 5-day endpoint (day 47).
2.5. Histopathology
Histopathological evaluation was performed by a certified
and well-trained pathologist on haematoxylin–eosin (HE)-
stained 5m paraffin sections of formalin-fixed lung tissue
fragments dissected at 1 and 5 days post-infection from naive,
non-immune, immune and immune potentiated chickens.
2.6. RNA isolation
Total RNA was isolated from lung and spleen samples
using a Trizol extraction method as described by the man-
ufacturer (Invitrogen Life Technologies, Paisley, UK) and
subsequently purified using the RNeasy Midi RNA Purifica-
tion kit (Qiagen Ltd., Crawley, UK). The RNA concentration
was determined spectrophotometrically and its quality by
using the Agilent 2100 Bioanalyser (Agilent Technologies,
Waldbronn, Germany). RNA was treated with DNaseI as
described by the manufacturer (Ambion Ltd., Huntingdon,
Cambridgeshire, United Kingdom).
2.7. Real-time quantitative RT-PCR
Presence of AI-H9 viral RNA in the lungs of naive and
infected chickens was quantitated using real-time quantitative
RT-PCR (Q-RT-PCR). Primer sequences for H9 and chicken
GAPDH are depicted in Table 2. GAPDH is being used as
the housekeeping control gene as this molecule proved to be
more stable than-actine (data not shown). Eight micrograms
of total RNA was reverse-transcribed into cDNA using the
Superscript II RT protocol (Invitrogen Life Technologies) in
a 30-l reaction. After dilution of the reaction mixture with
15l H2O, 2l of template cDNA was used for each Q-
PCR, which was performed in single wells of a 96-well plate
(ABgene, Epsom, Surrey, United Kingdom) in a 50l reac-
tion volume. The 50l reaction mixture contained 28.5l
H2O, 5.0l iCycler mixture (without Triton and MgCl2),
Table 2
Real time quantitative RT-PCR primers
RNA target Primer sequence (5′–3′) Accession No.
GAPDH F GTGGTGCTAAGCGTGTTATC K01458
R GCATGGACAGTGGTCATAAG
AI-H9 F GGTCAGACATTGCGAGTAAG AF461530
R CTAGCAGGCACATTCCTCAG
5.0l 25 mM MgCl2, 4.0l 2 mM dNTPs, 2.0l of a 10M
forward and reverse primer mix, 2.5l 20× EvaGreen dye
(Biotium Inc., Hayward, CA) and 1.0l 5 U/l Supertaq
(HT Biotechnology). Amplification and detection of spe-
cific products were performed using the iCycler (BioRad,
Hercules, CA) with the following cycle profile: 1 cycle of
95 ◦C for 5 min, and 40 cycles of [92 ◦C for 10 s, 55 ◦C for
10 s, 72 ◦C for 30 s] and 1 min 72 ◦C for a final extension.
Fluorescence was measured following each cycle and dis-
played graphically (iCycler iQ Multicolor Real-Time Detec-
tion System, Optical System Software, version 3.1, BioRad,
Hercules, CA). The software determined a cycle threshold
(Ct) value, which identified the first cycle detecting the fluo-
rescence above the baseline for that sample or standard.
The GAPDH and H9 PCR-fragments were also cloned and
used in combination with the Q-RT-PCR primers to calculate
the slopes from log10 dilution series regression lines. To cor-
rect for differences between template RNA levels between
samples within an experiment, first the difference factor (DF)
(normalization factor) for each sample was calculated by
dividing the mean Ct value for GAPDH-specific product of
a sample by the mean Ct value for GAPDH-specific prod-
uct for all samples. The corrected H9 RNA per sample was
calculated using the following formula [15]:
(40 − mean H9 Ct sample) × H9 slope
DF sample × GAPDH slope
Results are expressed as standardized 40-Ct values.
2.8. cDNA microarray
Construction of the cDNA libraries, EST sequence analy-
sis, construction of the microarray containing 5007 elements
(in duplicate), RNA labeling, hybridizations and data extrac-
tion were all performed as described in the paper by Smith et
al. [13]. For the hybridizations a reference design approach
was used in which all samples from all treatments were pooled
and compared with individual treatment samples. The refer-
ence and treatment samples were labeled using the dye flip
approach, i.e. the reference and treatment samples were cross-
labeled and hybridized to two arrays.
2.9. Data analysis
Data was extracted from individual slides using the
Bluefuse software (BlueGnome, Cambridge, UK) after which
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features with poor confidence information (confidence <0.30)
were eliminated from the analysis. Background-corrected
signal values were imported into the VectorNTI Xpres-
sion 3.1 software (Invitrogen Life Technologies, Paisley,
UK) for comprehensive analysis. M versus A calculation,
where M = log 2 (sample/reference) and A = 0.5 log 2 (sam-
ple × reference), Lowess normalization and finally anti-log
transformation of M were applied. The [sample/reference]
ratios, i.e. the anti-log 2 M values, from slides with simi-
lar treatments were pooled and compared with other treat-
ments using the Student’s t-test. Only genes with a signifi-
cant (P < 0.05) difference between two treatments were used
for further calculations. Final gene expression fold changes
were calculated by dividing the [sample/reference] ratio of
a gene from a treatment by the [sample/reference] ratio of
that same gene in the naive group. Only ratios with a fold
change ≥1.5 are shown. The raw data files can be found at
[www.ebi.ac.uk/arrayexpress].
2.10. Statistical analysis
Comparison of the levels of up- or down-regulation
(microarray data) was performed with the VectorNTI Xpres-
sion 3.1 software package (see above). To analyze the Q-PCR
and HI-antibody data we used analysis of variance (ANOVA)
with least significant difference (L.S.D.) as multiple com-
parison test. Differences were considered significant at a
confidence level of 95% (P < 0.05).
3. Results
3.1. Pathology of H9N2 infection
No evidence of gross clinical pathology was noted in
infected animals, similar to earlier unpublished studies with
this H9N2 virus (data not shown). The lungs of naive chickens
infected with H9N2, similar to those of immune or immune
potentiated birds, showed little gross pathology at macro-
scopic inspection during necropsy (not shown). However,
upon microscopic examination by a certified and well-trained
pathologist, profound differences were noted in the lungs of
non-immune, immune and immune potentiated infected birds
at 5 days post-infection (Fig. 2).
In non-immune infected animals the lungs showed necro-
sis of parabronchial epithelium, edema, and fibris exudation
in airways and air capillaries indicating severe pneumonia
(Fig. 2B). Next to this, diffuse infiltration of lymphoid cells
Fig. 2. Microscopic histopathology of lung tissue at day 5 after oculo-nasal-intratracheal H9N2 infection. Inoculated chickens were either naive not challenged
(A), non-immune challenged (B), immunized with antigen in saline (immune) and challenged (C), or immune potentiated as a result of H9N2 antigen formulated
in W/O immunopotentiator and challenged (D). Sections were stained with HE; magnification at 40×. Data representative of two experiments are shown.
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Fig. 3. Virus-specific avian influenza H9 expression levels in the lungs of
chickens as measured by real time quantitative RT-PCR analysis. Results
are expressed as standardized 40-Ct values corrected for variation in input
RNA measured by GAPDH levels. As values are subtracted from 40, higher
values represent higher levels of expression. Inoculated chickens were either
naive not challenged, non-immune challenged, immunized with antigen in
saline (immune) and challenged, or immune potentiated as a result of H9N2
antigen formulated in W/O immunopotentiator and challenged. Error bars
are S.E.M. for three samples from each treatment group analyzed in duplo.
*Significantly different (P < 0.05) from the naive group.
was noticed at higher magnification (not shown). In com-
parison, the lungs of animals immunized before with H9N2
in saline only (immune infected birds), showed less dra-
matic fibrinous exudate in the airways (Fig. 2C) indicating
moderate/mild pneumonia, with isolated foci of clustered
immune cells (not shown). The airways of chickens immu-
nized with H9N2 antigen formulated in an immunopotenti-
ating W/O delivery system proved minimally affected with-
out obstruction by fibrinous exudate (Fig. 2D). The lungs
showed little recruitment of immune cells and minimal areas
of lymphoid cell infiltration at higher magnification (not
shown).
3.2. Detection of H9N2 virus in naive and immunized
hosts
Using quantitative RT-PCR (Q-RT-PCR) employing
primers specific for the H9 sequence of avian influenza we
noted clear evidence of viral replication at days 1 and 5 in the
lungs of non-immune infected birds (Fig. 3). The lungs from
immune animals still showed H9 gene detection especially
on day 5. By contrast, immune potentiated animals showed
strongly reduced viral replication.
3.3. Speciﬁc antibody formation in immunized chickens
In blood samples taken 3 weeks post-vaccination, i.e.
1 day before challenge infection, H9N2-specific HI serum
antibodies were measured in individual birds of all groups.
Immune birds, vaccinated with H9N2 in saline, showed no
detectable antibody titers, while immune potentiated animals,
vaccinated with H9N2 in a W/O emulsion, showed a readily
detectable serum HI titer (Fig. 4).
Fig. 4. H9N2 specific HI-antibody responses at 3 weeks after primary immu-
nization. Immunized chickens were either naive (saline control), immunized
with H9N2 antigen in saline only (immune), or immune potentiated as a
result of H9N2 antigen formulated in W/O immunopotentiator (W/O). *,
Significantly different (P < 0.05) from the naive and immune group.
3.4. Immunophenotyping of host responses in lung tissue
and spleen
In order to obtain more detailed information about
immunity-related responses in the lungs and spleen of chick-
ens we used microarray-assisted ex vivo gene expression
profiling on lung and spleen tissue isolated at 1 and 5 days
after oculo-nasal-intratracheal infection. For this, a reference
design combined with a dye flip approach was used (see Sec-
tion 2.8).
Fig. 5 gives an overview of the total amount of sig-
nificantly (P < 0.05) changed (fold change ≥1.5) genes in
the lungs (A–D) and spleens (E–H) between the indi-
cated treatments relative to organs of naive uninfected
birds on day 1 and day 5. In the lungs of non-immune
infected birds 10.3% ([(202 + 387) − 74]/5007 × 100%) of
all genes on the array show a greater than 1.5-fold reg-
ulation. This percentage drops to 9.1% and 8.3% in the
immune and immune potentiated birds, respectively, sug-
gesting that immune potentiated birds, who received anti-
gen formulated in immunopotentiator, exhibited less immune
activation to control the virus, when compared to immune
and non-immune birds. For spleen we noted the same phe-
nomena with percentages of 4.0%, 3.1% and 3.1% for non-
immune, immune and immune potentiated birds, respec-
tively. The number of genes, common in the lungs on day
1 and day 5 post-infection, ranges between 74, for the non-
immune birds, and 51, for the immune potentiated birds.
Remarkably, only 3 genes are common on day 1 and day
5 in the spleens of immune potentiated birds (13 for the
non-immune and 17 for the immune animals). In general,
when comparing the gene expression regulation in lung
and spleen it is obvious that the spleen is relatively quiet.
Subsequently, detailed analysis focussed on genes with an
available well-known (putative) immunological annotation,
which showed significant (P < 0.05) regulation (fold change
≥1.5).
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Fig. 5. Analysis of host responses to avian influenza H9N2. Patterns of gene expression in whole lungs and spleens of non-immune (n-immune), immune
and immune potentiated (immune p) chickens at 1 or 5 days post-infection with H9N2 influenza virus, via the oculo-nasal and intratracheal route, are shown.
(A–C, E–G) Venn diagrams show overlap of genes with ≥1.5-fold (P < 0.05) regulation. The heat maps were made using an unweighted average hierarchical
clustering algorithm and the Euclidean distance matrix. Genes shown in red were up-regulated, while genes shown in green were down-regulated. (D and H)
Total numbers of up- or down-regulated genes are indicated. (For interpretation of the references to color in this figure legend, the reader is referred to the web
version of the article.)
3.5. Microarray-assisted immunogenomic analysis
Using the reference design approach, we examined signif-
icant gene expression differences of non-immune infected,
immune infected and immune potentiated infected animals
when compared to naive uninfected (saline) hosts. Conspic-
uous genes in the lungs and spleen, with a well-known
immunological annotation, are depicted in Tables 3 and 4,
respectively. Measured gene responses were divided into
those associated with known innate immune pathways and
genes involved in adaptive immune pathways. As the func-
tional annotation of chicken genes lags dramatically behind
similar work achieved in mammals (i.e. mainly mice), we
can only assume that most of the chicken genes, which
are printed on the micro-array, function in a similar man-
ner as the mammalian molecules. As the chicken genome
was released just recently [5], it may take years before all
putative orthologues have been characterized and function-
alized. The critical reader should therefore be aware of the
fact that if an annotation suggests that a chicken gene is an
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Table 3
Regulation of well-known immunologically relevant genes in lungs of AI-H9N2 infected chickens
Gene Accession
number
Non-immune vs. naive Immune vs. naive Immune potentiated vs. naive
1 d 5 d 1 d 5 d 1 d 5 d
Innate immune pathway
Chemokines and receptors
Chemokine receptor-like 2
protein
BU444213 1.7 (0.016) 1.8 (0.047) 1.7 (0.036) 2.4 (0.014)
Chemokine AH221 AM064266 2.6 (0.0001) 1.9 (0.002)
Chemokine AH294 (RANTES) BU397782 2.6 (0.049)
Chemokine-like factor AM066499 −1.6 (0.036)
CXCL12 (chemokine) AM064247 2.3 (0.017)
SCYa4 (chemokine) BU299262 −2.2 (0.048)
SCYa13 (TNF inducible
gene)/MCP-4 chemokine
BU397023 3.0 (0.019) 3.5 (0.025)
Macrophage/myeloid cells
MARCO (scavenger receptor) AM064405 2.6 (0.048) 1.7 (0.043) 3.2 (0.026) 2.1 (0.038)
MIF (macrophage migration
inhibitory factor)
BU438017 −1.5 (0.048) −1.9 (0.047)
MCSF-R (macrophage colony
stimulating factor) receptor
BU432910 1.9 (0.016)
NRAMP2 (natural
resistance-assoc. macrophage
protein)
BU203948 −1.8 (0.003)
Toll-pathway
TLR2 (Tol-like receptor 2)
type 1
BU374739 2.9 (0.042) 10.3 (0.050) 4.6 (0.002) 5.5 (0.002) 3.9 (0.024)
TLR4 (Tol-like receptor 4) BU475859 −1.8 (0.048)
NF-B1 nuclear factor AM063779 −1.6 (0.016) −1.8 (0.001) −1.6 (0.031) −1.8 (0.011)
IFN-pathway
IFP35 (IFN-induced 35 kDa
protein)
BU135331 2.3 (0.005) 2.5 (0.009)
IRF3 (IFN-regulatory factor 3) AM070266 −1.7 (0.029)
IRF4 (IFN-regulatory factor 4) AM072251 2.5 (0.048) 2.6 (0.026) 2.7 (0.036) 3.5 (0.008) 2.7 (0.016)
IRF5 (IFN-regulatory factor 5) AI981854 −2.9 (0.048)
IRF8 (IFN-regulatory factor 8) AM065010 2.4 (0.036) 1.9 (0.012) 1.7 (0.018)
Heat shock proteins (HSPs)
Hsp70 AM070074 6.1 (0.008) 4.5 (0.008) 5.5 (0.042) 3.3 (0.027)
Hsp70 protein 12B AM065354 −1.6 (0.009)
Hsc70.II (heat shock cognate
70.II protein)
AM069279 1.8 (0.024) 1.8 (0.024)
Hsp90 AM068283 1.7 (0.044) 1.6 (0.034)
Complement factors
Complement C3 AM067441 1.8 (0.027) 1.9 (0.026) 1.6 (0.037)
Complement inhibitory factor H AM063703 −1.6 (0.048)
Pro-inflammatory cytokines
IL-6 AI982185 2.2 (0.009) 2.1 (0.002)
Proteases
Granzyme M (NK cell granular
protease)
AM071672 2.0 (0.023) 2.0 (0.027) 1.8 (0.041) 2.7 (0.005)
Adaptive immune pathway
Antigen presentation
Cathepsin S AM067017 2.7 (0.037) 2.1 (0.042)
Class I alpha AM068770 3.4 (0.003) 2.3 (0.038) 2.4 (0.002)
Class I B–F heavy AM067119 2.6 (0.026) 1.7 (0.008)
Class I minor AM068728 2.0 (0.019)
Class II B–LBII-beta AM068054 −1.6 (0.029)
Cytokines and receptors
Cytokine receptor common beta
chain precursor
AM066518 −1.5 (0.048) −1.8 (0.035) −1.6 (0.043)
IL-2Rb AM064890 1.6 (0.002)
IL-4R BU324362 −1.5 (0.021)
IL-13R2 BU341330 2.9 (0.009) 3.7 (0.013)
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Table 3 (Continued )
Gene Accession
number
Non-immune vs. naive Immune vs. naive Immune potentiated vs. naive
1 d 5 d 1 d 5 d 1 d 5 d
IL-20Ralpha BU241765 −2.2 (0.036) −2.0 (0.048)
IFN-R2 BU294744 1.9 (0.015)
IL-15 BU202444 −2.0 (0.019)
IK cytokine AM070735 −1.9 (0.017)
CD and T cell markers
CD2 (expression: T cells,
thymocytes, NK cells)
AM068706 −1.7 (0.029)
CD200 (expression: DCs,
activated T cells)
AI981679 1.7 (0.006)
CD3 (expression: thymocytes, T
cells)
AM070515 1.5 (0.038) 2.3 (0.24) 1.7 (0.013) 2.7 (0.00006) 1.8 (0.004)
CD4 (expression: Th cells,
monocytes, macrophages)
AM075583 2.3 (0.012)
CD5 (expression: thymocytes, T
cells, subset of B cells)
AM071524 2.4 (0.013) 2.4 (0.001) 2.4 (0.012)
CD8 (expression: subset
thymocytes, cytotoxic T cells)
AM069615 2.2 (0.032)
TCRzeta (T cell receptor zeta) AM069278 2.0 (0.029)
Transcription factors
GATA-3 (Th2 transcription
factor)
AM064179 2.0 (0.036) 2.1 (0.003)
Cystatin F (cytokine-like
nuclear factor)
AM070770 2.0 (0.034)
Cytokine signaling suppressors
SOCS1(suppressor of cytokine
signaling 1)
BU218362 −1.6 (0.048)
SOCS5 (suppressor of cytokine
signaling 5)
BU326390 1.7 (0.038)
B cell
Ig J chain AM064723 3.3 (0.048) 3.7 (0.036) 12.2 (0.011) 3.4 (0.036) 5.2 (0.009)
Ig mu chain C region AM067797 2.2 (0.050) 2.2 (0.024)
Ig light chain VJC region AM064528 2.5 (0.003) 2.8 (0.005) 2.5 (0.001)
Ig lambda chain C region AM072032 2.5 (0.002) 2.2 (0.01) 2.3 (0.024)
Miscelaneous
Apoptosis
anti-apoptotic NR13 AM071765 1.5 (0.037)
Death receptor 6 (mediates
apoptosis; TNF family member)
AM066244 2.0 (0.028) 2.1 (0.039)
FasL decoy receptor 3 (inhibits
FasL/TNF apoptosis)
AM064070 1.5 (0.028)
TNF-related
TRAF1 (TNF
receptor-associated factor 1)
AI982046 1.5 (0.021)
TRAF2 (TNF
receptor-associated factor 2)
BU455745 1.8 (0.009)
TRAF5 (TNF
receptor-associated factor 5)
BU455745 2.1 (0.029) 2.1 (0.031)
Regulation (≥1.5-fold; P < 0.05) of well-known immunologically relevant genes in the lungs of non-immune, immune or immune potentiated chickens at 1 or
5 days post-infection with avian influenza H9N2 when compared to naive control birds. P values are between parentheses.
orthologue it might not function in a similar manner as in
mammals.
3.5.1. Innate immune responses
3.5.1.1. Chemokines and receptors. Chemotactic migration
of leukocytes largely depends on adhesive interactions with
the substratum and recognition of a chemoattractant gradient
provoked by chemokines. Increased expression of the TNF
inducible gene SCYa13 (mcp-4 chemokine or small inducible
A13 cytokine precursor), was noted on day 1 only in both the
lungs and spleens of non-immune and immune infected birds
(Tables 3 and 4). In the lungs of non-immune and immune
infected birds chemokine receptor like protein 2 was also
significantly up-regulated at day 1 in both groups, and at day 5
in the non-immune group, while the chemokines AH221 and
AH294 (RANTES), but only in the non-immune group, were
6104 W.G.J. Degen et al. / Vaccine 24 (2006) 6096–6109
Table 4
Regulation of well-known immunologically relevant genes in spleens of AI-H9N2 infected chickens
Gene Accession no. Non-immune vs. naive Immune vs. naive Immune potentiated vs. naive
1 d 5 d 1 d 5 d 1 d 5 d
Innate immune pathway
Chemokines and receptors
Chemokine AH221 AM064266 2.8 (0.026) −1.7 (0.020) 2.8 (0.0020) 2.0 (0.036)
CXC-R4 (chemokine receptor) AM069849 −1.6 (0.018)
SCYa13 (TNF inducible
gene)/MCP-4 chemokine
BU397023 3.5 (0.008) 3.7 (0.0003)
Macrophage/myeloid cells
MARCO (scavenger receptor) AM064405 −1.6 (0.026)
Toll-pathway
TLR2 (Tol-like receptor 2)
type 1
BU374739 3.0 (0.014)
IFN-pathway
IFP35 (IFN-induced 35 kDa
protein)
BU135331 2.1 (0.0004) 1.8 (0.001)
Heat shock proteins (HSPs)
Hsp70 AM070074 1.8 (0.020)
Complement factors
Complement C1r-like
proteinase
AM065161 1.5 (0.019) 1.7 (0.050) 1.9 (0.006)
Complement C1qB AM065730 2.0 (0.048) 2.0 (0.024)
Complement C1qC AM067767 −1.6 (0.017)
Adaptive immune pathway
Antigen presentation
Cathepsin S AM067017 1.9 (0.014) 1.8 (0.001) 2.5 (0.020) 1.6 (0.036)
Class I B-F heavy AM067119 1.7 (0.037)
Cytokines and receptors
Cytokine receptor common
beta chain precursor
AM066518 1.6 (0.035)
IL-13R2 BU341330 3.1 (0.020)
IFN-R2 BU294744 1.6 (0.020)
CD and T cell markers
CD200 (expression: DCs,
activated T cells)
AI981679 1.6 (0.042)
CD226 (expression: Th1 cells) AI980296 −1.8 (0.028)
CD5 (expression: thymocytes,
T cells, subset of B cells)
AM071524 −2.1 (0.022)
CD84 (expression: monocytes,
platelets, circ. B cells)
AM070961 −1.5 (0.048)
Transcription factors
GATA-3 (Th2 transcription
factor)
AM064179 2.1 (0.006)
B cell
Ig J chain AM064723 −1.5 (0.048)
Ig rearranged heavy chain VDJ
region
BU398082 −4.8 (0.048)
Ig lambda chain C region AM072032 −1.5 (0.031)
T cell activation and differentiation
Ly6e (SCA-2/TSA1) AM071100 3.6 (0.004)
Miscelaneous
Apoptosis
Bcl-2-like AM071676 1.6 (0.048)
Regulation (≥1.5-fold; P < 0.05) of well-known immunologically relevant genes in the spleens of non-immune, immune or immune potentiated chickens at 1
or 5 days post-infection with avian influenza H9N2 when compared to naive control birds. P values are between parentheses.
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up-regulated at day 5 only (Table 3). In the spleen of immune
birds AH221 is up-regulated on day 1 and 5, and only on day
1 in non-immune birds (Table 4). Remarkably, limited up-
regulation of chemokines and chemokine receptors was noted
in the lungs of immune potentiated infected birds except for
the CXCL12 chemokine, which is up-regulated at day 1, and
chemokine receptor like protein 2 at day 5 (Table 3).
3.5.1.2. Macrophage/myeloid cells. The scavenger receptor
MARCO (macrophage receptor with collagenous structure),
a molecule involved in specific recognition and defense
against pathogens as well as differentiation of monocytes
into dendritic cells, proved selectively expressed at day 1
in non-immune, immune and immune potentiated infected
birds, and also at day 5 post-infection in immune potentiated
birds (Table 3). In MARCO-deficient mice it was shown that
this molecule plays an important role in mounting an efficient
and appropriately regulated innate immune response against
inhaled particles and airborne pathogens [16].
3.5.1.3. Toll-pathway. The recognition of microbes by
innate immune cells is crucial for initiation of antigen pre-
sentation and down-stream activation of adaptive immune
reactions. Toll-like receptors (TLRs) are known to recognize
various components of invading pathogens. TLR4, the recep-
tor for bacterial lipopolysaccharide (LPS), is down-regulated
in non-immune infected birds at day 1 (Table 3). Interest-
ingly, TLR2 type 1 [17], the receptor for bacterial cell wall
components, was up-regulated in non-immune and immune
infected animals at days 1 and 5, and at day 1 in immune
potentiated birds only. The selective up-regulation of TLR2
type 1 expression with concomitant decrease of TLR4 expres-
sion at day 1 in non-immune birds maybe due to either influx
of distinct innate immune cells, such as antigen present-
ing cells, or selective regulation of receptor expression on
one cell population. TLR2 type 1 is also up-regulated in
the spleens of immune birds on day 5 (Table 4). In paral-
lel with the up-regulated MARCO receptor and TLR2 type
1 mRNA molecules, all groups showed increased expression
of granzyme M, a granular protease associated with NK cells
at day 1.
3.5.1.4. IFN-pathway. Upon viral infection, production of
type-I interferon (IFN) and IFN-induced genes is a typical
innate defense response resulting in an antiviral state of non-
infected neighboring target cells. Type I IFN is also known
to act as an important immune inducer and immunoregula-
tory factor. A number of genes associated with an activated
type I IFN-pathway were noted especially in the lungs of
non-immune and immune infected chickens (Table 3). Acti-
vated genes included IFN associated IRF4/MUM1 (inter-
feron regulatory factor 4), – also involved in controlling
B-cell proliferation and differentiation, and proliferation of
mitogen-activated T cells – showed similar up-regulation at
days 1 and 5 after infection in non-immune and immune
hosts (Table 3). In addition, type I IFN-pathway transcrip-
tion factor IRF8, showed up-regulation specific for lungs
of chickens immunized with antigen only at days 1 and 5
after infection and in immune potentiated birds at day 1
(Table 3). The IFN-induced protein IFP35 showed selectively
increased expression at day 1 in the lungs and spleens of non-
immune and immune infected birds (Tables 3 and 4). The
IFN pathway genes IFP35, IRF4 and IRF8 noted in lungs of
chickens receiving antigen only (immune infected), suggest
that viral replication was not completely blocked as a result
of immunization with antigen in saline only. This hypothesis
is consistent with Q-PCR detection of the viral haemagglu-
tinin gene (see above). However, in H9N2-infected chickens
immunized with antigen in immunopotentiating adjuvant, the
immune potentiated group, only IRF4 and IRF8 were up-
regulated, on days 5 and 1, respectively (Table 3).
3.5.1.5. Heat shock proteins (HSPs). The main function of
heat shock proteins (HSPs) is to act as chaperones of nascent
or abnormally folded proteins. However, from an immuno-
logical point of view HSPs have obtained increasing interest
since they may act as endogenous immune-activating “dan-
ger” signals. Hsp70 and Hsp90 expression was clearly
up-regulated at days 1 and 5 in immune potentiated birds
(Table 3), while Hsc70II showed up-regulation in, especially
lungs of, non-immune chickens on day 1.
3.5.1.6. Complement factors. The complement system con-
sists of several plasma proteins, i.e. complement factors, that
act together to attack extracellular pathogens. Up-regulation
of complement C3 mRNA was noted only in non-immune
infected birds at day 5 and in immune and immune potentiated
infected birds at day 1 (Table 3). Complement inhibitory fac-
tor H was down-regulated in non-immune animals on day 1
after challenge only. Remarkably, in spleens of non-immune
and immune infected birds, but not in immune potentiated
animals, complement C1 proteins, i.e. C1r-like and C1qB,
are commonly up-regulated (Table 4).
3.5.1.7. Pro-inﬂammatory cytokines. Secretion of pro-
inflammatory cytokines, such as tumor necrosis factor (TNF),
interleukin (IL-1) and IL-6, is one of the early reactions of the
host against infection. A combined action of these cytokines
causes fever, leukocytosis and the production of acute phase
proteins. At 1 day after infection, lungs of non-immune and
immune infected birds, show up-regulated gene expression
of interleukin-6 (IL-6) (Table 3). However, expression of this
pro-inflammatory cytokine was not altered in the lungs of
immune potentiated animals.
3.5.2. Adaptive immune responses
3.5.2.1. Antigen presentation. Increased antigen presenta-
tion to CD8 positive T cells was suggested by the up-
regulation of class I alpha, class B–F heavy and class I
minor chains at day 5 after challenge in the lungs of non-
immune birds. This was, to a lower extent, also observed in
lungs of immune and immune potentiated animals (Table 3).
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Cathepsin S, a key protease responsible for the removal of the
invariant chain from MHC class II molecules, is up-regulated
at day 1 in the lungs and spleens of non-immune and immune
infected birds. However, at day 5 cathepsin S is only up-
regulated in the spleens of immune and immune potentiated
birds (Tables 3 and 4).
3.5.2.2. CD markers and cytokine receptors. Up-regulated
expression of T cell-specific CD3 genes was noted in lungs
of non-immune and immune infected birds at days 1 and 5
and in immune potentiated birds at day 5 only (Table 3).
Remarkably, increased expression of CD4 and CD8 was evi-
dent especially in immune birds at day 1. These animals also
showed evidence of active up-regulation of cytokine recep-
tor expression, such as IL-2Rb on day 5, IL-13R2 on days 1
and 5, and IFN-R2 on day 1 (Table 3). Up-regulation of the
cytokine receptors IL-13R2 and IFN-R2 was also noted on
day 1 in spleens of immune and non-immune birds, respec-
tively (Table 4). Immune potentiated infected birds showed no
evidence of increased cytokine receptor expression in lungs
and spleen. Interestingly, no significant changes in the cor-
responding cytokine genes, such as IL-2, IFN- and IL-4,
were noted in any group on any point in time in lungs and
spleens when using the micro-array approach. Unfortunately,
the genes encoding IL-13, an important Th-2 cytokine, and
IL-20, a member of the IL-10 family of molecules associated
with putative regulatory T cell function, are not included on
this version of the microarray.
3.5.2.3. Transcription factors. At day 1 after infection lungs
of non-immune and immune birds, and spleens of immune
birds, show up-regulation of GATA-3, which is associ-
ated with Th-2 type T cell immune responses in mammals
(Tables 3 and 4). Lungs and spleens of immune potentiated
infected birds showed no altered GATA-3 gene expression
at any time-point. However, an increased expression of cys-
tatin F (leukocystatin) an immune cell restricted cysteine
proteinase inhibitor, which may play a role in antigen pre-
sentation [18], was observed at day 1 in lungs only (Table 3).
3.5.2.4. B cells. Influx onto or (re)activation of B cells in
infected lungs was suggested by the up-regulation of the
genes encoding various Ig chains especially at 5 days after
infection of non-immune, immune and immune potentiated
animals (Table 3). In all groups Ig chain expression concurred
with increased expression of CD5, a mammalian marker
of many B-1a but also B-2 B cells. The profound increase
of CD5 in immune birds on day 5 may be explained by
a booster effect as a result of the challenge infection. For
immune potentiated birds the level of responsiveness was
more modest, likely in view of pre-existing virus-neutralizing
antibodies in the circulation, which may immediately neutral-
ize (part of) the challenge infection.
3.5.2.5. Apoptosis and TNF-related gene expression.
Influenza virus has been shown to induce apoptosis in cells
that are permissive for viral replication and cells that do not
support viral replication. Influenza induced apoptosis likely
represents part of an overall beneficial immune response,
but, on the other hand, could also be a mechanism involved
in disease pathogenesis. In our study, granzyme M, a rep-
resentative of a new perforin-dependent cell death pathway
playing a significant role in cell death mediated by NK cells
[19], is up-regulated at day 1 after infection in the lungs
of all groups (Table 3). In addition, the anti-apoptotic pro-
tein NR13, a member of the Bcl-2 family, is up-regulated at
day 5 in immune infected lungs which co-incides with up-
regulation of granzyme M. TRAF-1 (tumor necrosis factor-
receptor associated factor-1) is an adaptor and signal trans-
duction molecule known to interact with the cytoplasmic
tail of TNF receptor 2 thereby linking it to different sig-
nal transduction pathways. TRAF1 inhibits antigen-induced
apoptosis in CD8 + lymphocytes [20]. This molecule showed
increased expression in lungs of non-immune chickens at
5 days after infection (Table 3). This coincided with up-
regulation of MHC class I chain genes. TRAF2 and TRAF5
showed up-regulation at day 1 in lungs of immune infected
birds, coinciding with CD3, CD4, CD8 and the FASL decoy
receptor 3 and death receptor 6 expression. Again, lungs
of immune potentiated infected birds showed no TRAF1,
TRAF2 or TRAF5 expression.
4. Discussion
Influenza virus infections may cause inflammatory pneu-
monia in all susceptible species. Control of an acute influenza
virus infection in naive hosts is thought to be based on innate
and subsequent adaptive cytotoxic T lymphocyte (CTL) and
B cell activity [21,22]. By contrast, readily available virus
neutralizing antibodies are believed to be largely responsible
for protection of immunized hosts, but not essential [22], as
demonstrated in murine models. However, the precise role of
host immune elements in the control of acute avian influenza
is unknown. In addition, the potential contribution of host
immune elements in pulmonary immunopathology in birds is
largely undefined. In this study we investigated the influence
of a respiratory infection of inbred broiler chickens with the
low pathogenic avian influenza H9N2 virus on lung pathol-
ogy and gene expression. We demonstrate for the first time
lung pathology (pneumonia) of the low pathogenic H9N2
virus and insights into the molecular interaction with its naive
natural host. In addition we examined molecular early host
responses to respiratory influenza A H9N2 virus infection in
immunized chickens infected via the respiratory route.
When considering the observed levels of virus-inhibiting
antibodies, as well as histopathology and viral Q-PCR
data, we anticipated that immune potentiated birds, immu-
nized with formalin-inactivated antigen formulated in W/O
immunopotentiator, needed less immune activation in their
lungs to control the virus, when compared to immune birds,
receiving antigen only. Conversely, in view of the observed
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immunopathology in the lungs and absence of antiviral anti-
bodies at the moment of infection we foresaw more vigorous
immune responsiveness following pulmonary infection of
non-immune birds, which exhibited viral Q-PCR positive
lungs.
Indeed, the patterns of gene expression noted in the dif-
ferent groups suggest most intense reactions in non-immune
animals, with a partial overlap in the immune birds immu-
nized with inactivated antigen in saline only. Similar to our
naive H9N2 infected chickens, the lungs of H1N2 infected
macaques, when analyzed by microarrays, showed induc-
tion of IFN and B cell activation pathways, though with
more overt clinical signs [23]. By contrast, immune poten-
tiated chickens showed insignificant responses for a number
of known innate and adaptive immune elements that were
noted in the less immune and naive birds, including TNF- and
apoptosis-related genes as well as proinflammatory IL-6, and
certain chemokines. Remarkably, in this immune potentiated
group no significant changes in any known immunoregula-
tory cytokine or cytokine receptor gene were noted at any
point in time.
Based largely on studies in mice, the first line of defense
against influenza virus has been shown to involve natural anti-
bodies produced by B-1 cells [24], which do not increase IgM
production nor proceed to immunoglobulin isotype switch-
ing. Indeed, we noted up-regulated expression of CD5, a
marker of many B-1a cells in mammals, in the lungs of
all groups at day 5. In addition, granulocytes, such as neu-
trophils, are prominent in acutely infected murine lungs and
believed to control initial viral replication. Indeed, granzyme
M, an NK cell specific protease was significantly expressed
at day 1 in the lungs of all groups. Recent studies in IL-1
receptor deficient mice, however, suggest no major contri-
bution for neutrophils in the clearance of influenza [25]. We
noted no increased expression of chicken IL-1 mRNA in any
of the treated groups. However, increased expression of IL-
6, another pro-inflammatory mediator, was noted in lungs
of non-immune and immune (antigen-primed) birds at day 1
only.
As yet, the gene encoding for tumor necrosis factor alpha
(TNF-) has not been identified in the chicken and is there-
fore not available for monitoring. However, TRAF1, TRAF2,
TRAF5, the TNF family member Death receptor 6 and the
FasL decoy receptor 3, showed up-regulation especially in
lungs of immune birds. In mice TNF- is involved in recruit-
ment of inflammatory cells to the lung and the severity
of disease, while leaving virus clearance unaffected [26].
In the same model the initiation of infection-induced lung
injury proved to depend on TNF- expressed by Ag-specific
CD8+ T cells, recognizing Ag expressed by alveolar epithe-
lial cells [27]. TNF- neutralization in vivo or TNF receptor
(p55) gene deletion inhibited weight loss and lethality [27].
This was associated with minimal macrophage infiltration
and reduced expression of the murine monocyte chemokine
attractant gene-1 (MCP-1), at least one of the chemokines
produced by target epithelial cells [27]. In vivo neutral-
ization of MCP-1 significantly reduced inflammation and
immunopathology. In our studies evidence for macrophage
gene expression was noted for MARCO in the lungs of non-
immune, immune and immune potentiated infected birds at
day 1, and also at day 5 in immune potentiated birds (Table 3).
The chemokine AH294 (RANTES), which is produced by
influenza infected epithelial cells [28], and selectively up-
regulated especially in non-immune infected lungs at day
5 (Table 3), has been reported to facilitate activation and
extravasation of macrophages [29]. Genes associated with
MHC class I presentation were evident especially in the non-
immune infected group at day 1 and day 5, but less prominent,
and possibly less needed, in the immune and immune poten-
tiated group.
Collectively, our microarray data show that in all groups
IFN pathway genes are evident, although somewhat less in
immune potentiated birds, possibly explained by inhibited
viral replication. The up-regulation of IFN pathway genes
suggests that expression of these genes may be important in
initiating the antiviral response. Remarkably, however, we
could neither detect MX (a protein induced by IFN that
inhibits influenza virus and which is highly polymorphic
in chicken) nor IFN-. In addition, all groups show up-
regulated genes involved in MHC-class I presentation, CD5
and B cell immunoglobulin genes. Up-regulation of MHC
class I genes on day 5 are typical for lungs of non-immune
infected birds. Certain innate and adaptive immune reactions
are overlapping in both non-immune infected birds as well
as immune infected chickens, as reflected by up-regulated
chemokine receptor expression, and expression of TLR2 type
1, IFP35, IRF4, IL-6 as well as GATA-3. When compared to
other groups the lungs of chickens immunized with antigen
in saline only (immune), show relatively more CD marker
genes, IL-13R2, IFN-R2 and IL-2R2, hence more evidence
for adaptive immunoregulation pathways, as well as TNF
and apoptosis-related genes. By contrast, in the lungs of
immune potentiated birds innate response genes are rather
limited except for certain heat shock proteins, granzyme M
and MARCO, which, together with circulating antibodies and
T cells, are likely sufficient to control the challenge infection.
Remarkably, in the spleens of immune potentiated birds reg-
ulation of innate and adaptive immune response genes are
limited to only cathepsin S up-regulation at day 5.
Studies in mice revealed that in general Th-1 type immu-
nity involving IFN- producing T helper 1 cells [30] and
CD8 + CTL [31] are involved in the control of pulmonary
influenza infection. However, the pulmonary environment
generally promotes type-2 immune reactions [32]. Nasal-
pulmonary immunization of BALB/C mice with influenza
antigen alone induces increased Th-2 cytokine mRNA
expression (IL-4 and IL-5) in lung lymphocytes, which are
mainly CD4+ cells, but with no differences in Th-1 cytokine
mRNA (IFN- and IL-2) expression [32]. Conflicting murine
data exist on the role of IL-18. While in one study intranasal
influenza virus infection of IL-18 deficient mice resulted
in increased mortality as a result of reduced IFN- levels
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and poor NK cell activation [33], Van der Sluis et al. [34]
showed that IL-18 deficient mice had reduced viral loads and
enhanced CD4+ T cell activation and normal IFN- levels
monitored by intracellular staining. Interestingly, however,
studies in mice with null mutations of the receptors for IFN-
/, IFN- or both IFNs showed no major differences in the
control of acute or secondary intranasal influenza virus infec-
tion [21], suggesting a general redundancy of the IFN system
to pulmonary influenza immunity. Also, IFN- deficient mice
show almost no impaired resistance to intranasal influenza
infection [35], a skewing towards Th-2 characteristic IL-4 and
IL-5 production and associated IgG1 antibody isotype. Our
microarray data revealed profound up-regulation of the Th-2
response associated IL-13R2 and GATA-3 genes, but unfor-
tunately no clear evidence for selective recruitment or activa-
tion of Th-1 or Th-2 polarized cytokines, possibly to a lack
of detection sensitivity. Some key Th-2 associated chicken
cytokine genes like IL-13 and IL-4 were unknown until very
recently and only IL-4 is fortunately included on this version
of the microarray; although not significantly regulated.
In summary, respiratory infection using H9N2 influenza
A virus is useful to study respiratory immune reactions
to low-pathogenic influenza virus in lungs and spleen of
naive or immunized chickens. Evaluation of our preliminary
microarray data suggests gene pathways unique to or com-
mon among the differently immune groups. In that respect
prominent class I presentation genes are typical in lungs of
non-immune infected birds. Both non-immune and immune
(antigen only) infected birds show similarities in lung expres-
sion of chemokines, TLR2 type 1, and IL-6. All groups
showed up-regulation of IFN pathway genes, together with
genes involved in MHC class I antigen presentation, as well
as genes encoding CD5 and Ig. In the lungs of immune
potentiated birds we noted minimal innate responses, lim-
ited to HSPs, which, likely together with existing antibodies
and effectively primed T cells, are sufficient to control the
pulmonary infection. Also, in the spleens of immune poten-
tiated birds well-known immune responses at the molecular
level are not detectable. Lungs of birds that received anti-
gen only (immune) typically show prominent expression of
CD4 and CD8 genes, as well as genes encoding IL-13R,
IFNR, TRAF2 and TRAF5. Further in vivo studies address-
ing the functional contribution of selected up-regulated gene
products, their association with certain cell types and tran-
scriptional regulation will help to delineate influenza virus-
induced immunopathology and (cross-protective) immunity.
Such information may reveal new targets for disease inter-
vention in the natural host or may provide a model for other
species including man.
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